Ilya Rachman
Vermögen: 9 Mio $ am 31.07.2026
Vermögen: 9 Mio $ am 31.07.2026
Ilya Rachman is the founder of Immix Biopharma, Inc., founded in 2012, holding the title of Chairman & Chief Executive Officer.
Dr. Rachman currently holds the positions of Chief Executive Officer, Secretary, and Director at Nexcella, Inc. Education history includes an MBA from the University of California, Los Angeles; graduate and doctorate degrees from the University of Illinois; and an undergraduate degree from the University of Iowa.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 22.05.2026 | 1.141.683 ( 1,6 % ) | 9 Mio $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMIX BIOPHARMA, INC. | Vorstandsvorsitzender | 01.01.2012 |
Nexcella, Inc.
Nexcella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell therapies for AL amyloidosis and immune-mediated diseases | Vorstandsvorsitzender | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immix Biopharma, Inc.
Immix Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for cancer patients | Health Technology |
Nexcella, Inc.
Nexcella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell therapies for AL amyloidosis and immune-mediated diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen